On September 25, 2017, FDA hosted a public meeting on Patient-Focused Drug Development for Hereditary Angioedema. FDA was interested in obtaining patient and caregiver perspectives on the impact of Hereditary Angioedema on daily life and patient views on treatment approaches. For more information, visit the meeting webpage: https://go.usa.gov/xANw9
Public Meeting: Patient-Focused Drug Development for Hereditary Angioedema (Part 1 of 2)
